Annovis to Present Buntanetap Data at AD/PD™ 2026 Conference
Event summary
- Annovis Bio will present data on buntanetap at the AD/PD™ 2026 conference in Copenhagen, Denmark, from March 17-21, 2026.
- Presentation #1 will focus on buntanetap's treatment effect in Parkinson's Disease (PD) patients, specifically regarding cognition and biomarker findings.
- Presentation #2 will provide an update on the ongoing Phase 3 trial for buntanetap in early Alzheimer's Disease (AD).
- Cheng Fang, Senior VP of Research & Development, will present both studies.
The big picture
Annovis is pursuing a novel approach to treating neurodegenerative diseases by targeting multiple toxic proteins with a single oral therapy. The AD/PD™ conference presentations represent a critical inflection point for buntanetap, as they offer a public assessment of its efficacy and safety. The crowded neurodegenerative therapeutic landscape necessitates strong clinical data to differentiate buntanetap and secure market share.
What we're watching
- Clinical Efficacy
- The biomarker data presented regarding buntanetap's effect on PD patients will be crucial in validating its mechanism of action and potential for broader application, and will likely influence investor sentiment.
- Trial Enrollment
- Continued strong enrollment in the Phase 3 AD trial, as highlighted by Annovis, suggests a favorable investigator and patient response, but the timeline for results remains a key risk factor.
- Regulatory Pathway
- The success of buntanetap will depend heavily on the FDA’s assessment of the presented data, and the conference presentations may provide early indications of potential regulatory hurdles.
Related topics